Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients
<i>Background and Objectives:</i> To report the real-life Brolucizumab therapeutical outcomes of treatment-naïve and non-treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) and to analyze the incidence of therapy-related adverse events. <i>Materials and Me...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/59/6/1110 |
| _version_ | 1797593578587815936 |
|---|---|
| author | Carlo Gesualdo Settimio Rossi Clemente Maria Iodice Francesco Guarino Mariachiara Petrella Fabiana Anna D’Agostino Raffaele Perrotta Francesca Simonelli |
| author_facet | Carlo Gesualdo Settimio Rossi Clemente Maria Iodice Francesco Guarino Mariachiara Petrella Fabiana Anna D’Agostino Raffaele Perrotta Francesca Simonelli |
| author_sort | Carlo Gesualdo |
| collection | DOAJ |
| description | <i>Background and Objectives:</i> To report the real-life Brolucizumab therapeutical outcomes of treatment-naïve and non-treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) and to analyze the incidence of therapy-related adverse events. <i>Materials and Methods:</i> A total of 56 eyes of 54 patients diagnosed with nAMD were retrospectively evaluated over a 3-month follow-up. Naïve eyes received a 3-month loading phase, whereas non-naïve eyes were treated with one intravitreal injection + ProReNata scheme. The main outcome measures were best-corrected visual acuity (BCVA) and central retinal thickness (CRT) change. In addition, patients were stratified on the basis of fluid accumulation site, whether intra-retinal (IRF), sub-retinal (SRF), or sub-retinal pigmented epithelium (SRPE), to separately assess the eventual BCVA change in each subgroup. Finally, the incidence of ocular adverse events was evaluated. <i>Results:</i> In naïve eyes, a significant improvement of BCVA (LogMar) was observed at all timepoints from baseline (1 month-Mean Difference (MD): −0.13; 2 months MD: −0.17; 3 months MD: −0.24). In non-naïve eyes, a significant mean change was observed at all timepoints, with the exception of 1-month follow-up (2 months MD: −0.08; 3 months MD: −0.05). CRT significantly changed in both groups at all timepoints at a similar pace within the first two months, with naïve eyes displaying a larger overall thickness decrease at the end of the follow-up (Group 1 = MD: −123.91 µm; Group 2 = MD: −110.33 µm). With respect to the location of the edema, a significant BCVA change was observed in naïve patients with fluid in all three sites at the end of the follow-up (SRPE = MD: −0.13 (<i>p</i> = 0.043); SR = MD: −0.15 (<i>p</i> = 0.019); IR = MD: −0.19 (<i>p</i> = 0.041). Non-naïve patients exhibited significant mean BCVA changes only with respect to SR and IR fluid presence (SRPE = MD: −0.13 (<i>p</i> = 0.152); SR = MD: −0.15 (<i>p</i> = 0.007); IR = MD: −0.06 (<i>p</i> = 0.011). One naïve patient experienced acute-onset anterior and intermediate uveitis which completely resolved after therapy. <i>Conclusions:</i> Brolucizumab was demonstrated to be a safe and efficient alternative in improving both the anatomical and functional parameters of eyes with nAMD in this small, uncontrolled, series of patients. |
| first_indexed | 2024-03-11T02:11:17Z |
| format | Article |
| id | doaj.art-5a5f806f7fb24ee4be96dfcca5a24cdc |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-11T02:11:17Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-5a5f806f7fb24ee4be96dfcca5a24cdc2023-11-18T11:31:36ZengMDPI AGMedicina1010-660X1648-91442023-06-01596111010.3390/medicina59061110Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian PatientsCarlo Gesualdo0Settimio Rossi1Clemente Maria Iodice2Francesco Guarino3Mariachiara Petrella4Fabiana Anna D’Agostino5Raffaele Perrotta6Francesca Simonelli7Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania “Luigi Vanvitelli”, Via S. Pansini, 5, 80131 Naples, ItalyEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania “Luigi Vanvitelli”, Via S. Pansini, 5, 80131 Naples, ItalyEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania “Luigi Vanvitelli”, Via S. Pansini, 5, 80131 Naples, ItalyEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania “Luigi Vanvitelli”, Via S. Pansini, 5, 80131 Naples, ItalyEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania “Luigi Vanvitelli”, Via S. Pansini, 5, 80131 Naples, ItalyEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania “Luigi Vanvitelli”, Via S. Pansini, 5, 80131 Naples, ItalyEye Unit, G. Rummo Hospital, Via dell’Angelo, 1, 82100 Benevento, ItalyEye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania “Luigi Vanvitelli”, Via S. Pansini, 5, 80131 Naples, Italy<i>Background and Objectives:</i> To report the real-life Brolucizumab therapeutical outcomes of treatment-naïve and non-treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) and to analyze the incidence of therapy-related adverse events. <i>Materials and Methods:</i> A total of 56 eyes of 54 patients diagnosed with nAMD were retrospectively evaluated over a 3-month follow-up. Naïve eyes received a 3-month loading phase, whereas non-naïve eyes were treated with one intravitreal injection + ProReNata scheme. The main outcome measures were best-corrected visual acuity (BCVA) and central retinal thickness (CRT) change. In addition, patients were stratified on the basis of fluid accumulation site, whether intra-retinal (IRF), sub-retinal (SRF), or sub-retinal pigmented epithelium (SRPE), to separately assess the eventual BCVA change in each subgroup. Finally, the incidence of ocular adverse events was evaluated. <i>Results:</i> In naïve eyes, a significant improvement of BCVA (LogMar) was observed at all timepoints from baseline (1 month-Mean Difference (MD): −0.13; 2 months MD: −0.17; 3 months MD: −0.24). In non-naïve eyes, a significant mean change was observed at all timepoints, with the exception of 1-month follow-up (2 months MD: −0.08; 3 months MD: −0.05). CRT significantly changed in both groups at all timepoints at a similar pace within the first two months, with naïve eyes displaying a larger overall thickness decrease at the end of the follow-up (Group 1 = MD: −123.91 µm; Group 2 = MD: −110.33 µm). With respect to the location of the edema, a significant BCVA change was observed in naïve patients with fluid in all three sites at the end of the follow-up (SRPE = MD: −0.13 (<i>p</i> = 0.043); SR = MD: −0.15 (<i>p</i> = 0.019); IR = MD: −0.19 (<i>p</i> = 0.041). Non-naïve patients exhibited significant mean BCVA changes only with respect to SR and IR fluid presence (SRPE = MD: −0.13 (<i>p</i> = 0.152); SR = MD: −0.15 (<i>p</i> = 0.007); IR = MD: −0.06 (<i>p</i> = 0.011). One naïve patient experienced acute-onset anterior and intermediate uveitis which completely resolved after therapy. <i>Conclusions:</i> Brolucizumab was demonstrated to be a safe and efficient alternative in improving both the anatomical and functional parameters of eyes with nAMD in this small, uncontrolled, series of patients.https://www.mdpi.com/1648-9144/59/6/1110age-related macular degenerationanti-vascular endothelial growth factorbrolucizumabcentral retinal thicknessexudationintravitreal injection |
| spellingShingle | Carlo Gesualdo Settimio Rossi Clemente Maria Iodice Francesco Guarino Mariachiara Petrella Fabiana Anna D’Agostino Raffaele Perrotta Francesca Simonelli Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients Medicina age-related macular degeneration anti-vascular endothelial growth factor brolucizumab central retinal thickness exudation intravitreal injection |
| title | Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients |
| title_full | Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients |
| title_fullStr | Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients |
| title_full_unstemmed | Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients |
| title_short | Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients |
| title_sort | brolucizumab intravitreal injections for wet age related macular degeneration real life study on a cohort of italian patients |
| topic | age-related macular degeneration anti-vascular endothelial growth factor brolucizumab central retinal thickness exudation intravitreal injection |
| url | https://www.mdpi.com/1648-9144/59/6/1110 |
| work_keys_str_mv | AT carlogesualdo brolucizumabintravitrealinjectionsforwetagerelatedmaculardegenerationreallifestudyonacohortofitalianpatients AT settimiorossi brolucizumabintravitrealinjectionsforwetagerelatedmaculardegenerationreallifestudyonacohortofitalianpatients AT clementemariaiodice brolucizumabintravitrealinjectionsforwetagerelatedmaculardegenerationreallifestudyonacohortofitalianpatients AT francescoguarino brolucizumabintravitrealinjectionsforwetagerelatedmaculardegenerationreallifestudyonacohortofitalianpatients AT mariachiarapetrella brolucizumabintravitrealinjectionsforwetagerelatedmaculardegenerationreallifestudyonacohortofitalianpatients AT fabianaannadagostino brolucizumabintravitrealinjectionsforwetagerelatedmaculardegenerationreallifestudyonacohortofitalianpatients AT raffaeleperrotta brolucizumabintravitrealinjectionsforwetagerelatedmaculardegenerationreallifestudyonacohortofitalianpatients AT francescasimonelli brolucizumabintravitrealinjectionsforwetagerelatedmaculardegenerationreallifestudyonacohortofitalianpatients |